Brief: Immunovant Announces Imvt-1402, A Next Generation Anti-Fcrn

Immunovant

28/09/2022 15:50

Sept 28 (Reuters) - Immunovant Inc  IMVT.O :
    * IMMUNOVANT ANNOUNCES IMVT-1402, A NEXT GENERATION
ANTI-FCRN
    * IMMUNOVANT INC - PLAN TO SUBMIT IND AND INITIATE PHASE 1
STUDY
IN EARLY 2023 WITH INITIAL DATA EXPECTED IN MID-2023
    * IMMUNOVANT INC - PREVIOUSLY ANNOUNCED PROGRAMS FOR LEAD
ASSET
BATOCLIMAB CONTINUE AT FULL SPEED
    * IMMUNOVANT INC - CASH RUNWAY GUIDANCE INTO CALENDAR YEAR
2025
REMAINS UNCHANGED
    * IMMUNOVANT INC - IMVT-1402 IS ALSO EXPECTED TO HAVE
COMPOSITION
OF MATTER PATENT PROTECTION THROUGH AT LEAST 2042, ASSUMING
ISSUANCE OF PENDING PATENT
    * IMMUNOVANT - IN ANIMAL STUDIES, DEEP IGG LOWERING SIMILAR
TO
BATOCLIMAB WITH NO OR MINIMAL IMPACT ON ALBUMIN AND LOW-DENSITY
LIPOPROTEIN WAS OBSERVED

Source text for Eikon:  ID: 
Further company coverage:  IMVT.O 
 ((Reuters.Briefs@thomsonreuters.com;))